Abhisheak Sharma

Abhisheak Sharma, Ph.D.

Research Assistant Professor

Department: Pharmaceutics
Business Phone: (352) 273-7851
Business Email: asharma1@cop.ufl.edu

About Abhisheak Sharma

Abhisheak Sharma is a Research Assistant Professor of Pharmaceutics and Assistant Director of Translational Drug Development Core, University of Florida, Gainesville. He received his B. Pharm. from the Mohan Lal Sukhadia University, Udaipur, India in 2006 and became a registered pharmacist in India. He received his M. Pharm. in pharmaceutical chemistry from U. P. Technical University, Lucknow, India with a MHRD-Post-graduate fellowship (2006-2008) by All India Council for Technical Education (AICTE). He earned his Ph.D. in pharmacokinetics & metabolism from CSIR-Central Drug Research Institute, Lucknow, India. He was awarded Senior Research Fellowship during his graduate studies (2011-2015) by Indian Council of Medical Research (ICMR). After his graduate studies, Dr. Sharma did his post-doctoral research under the supervision of Dr. Bonnie A. Avery at the University of Mississippi (2015-2017) and University of Florida (2017-2019).

Accomplishments

Translational Research in Addiction Travel Award
2017 · Behavior, Biology, and Chemistry
Travel Award for Uppsala Pharmacometric Summer School
2014 · Novartis
Senior Research Fellowship
2011-2015 · Indian Council of Medical Research, Ministry of Health and Family Welfare
MHRD-Post-graduate fellowship
2006-2008 · All India Council for Technical Education

Research Profile

Abhisheak Sharma’s research focuses on the in vivo and in vitro preclinical pharmacokinetic studies of new chemical entities and natural products. He is proficient in various approaches to bioanalytical method development and validation of discovery compounds and plant alkaloids in different biological matrices (blood, dried blood spot, plasma, serum, tissue homogenates, and urine) using various analytical techniques (UPLC-MS/MS, UPLC-PDA-MS, and UPLC-PDA/FL). His research interests include translational development of new chemical entities to candidate drugs using PK-PD modeling and simulation approach. Dr. Sharma published more than thirty five peer-reviewed articles in highly respected journals and one book chapter in the field of pharmacokinetics and drug discovery. His research interests include: pharmacokinetics, drug development, drug-drug interaction, pharmacokinetic modeling and simulation

Open Researcher and Contributor ID (ORCID)

0000-0003-0553-4039

Areas of Interest
  • Bioanalysis
  • Drug Metabolism
  • Pharmacokinetics
  • Pharmacokinetics/pharmacodynamics
  • Population pharmacokinetics

Publications

2021
Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method.
Journal of pharmaceutical and biomedical analysis. 194 [DOI] 10.1016/j.jpba.2020.113778. [PMID] 33277117.
2020
Preliminary examination of mitragynine and 
7-hydroxymitragynine synthesis in response to production environment and postharvest techniques of Mitragyna speciosa
Acta Horticulturae. (1274):89-96 [DOI] 10.17660/actahortic.2020.1274.10.
2020
Pharmacokinetics and Safety of Mitragynine in Beagle Dogs.
Planta medica. 86(17):1278-1285 [DOI] 10.1055/a-1212-5475. [PMID] 32693425.
2020
Metabolism of a Kratom Alkaloid Metabolite in Human Plasma Increases Its Opioid Potency and Efficacy.
ACS pharmacology & translational science. 3(6):1063-1068 [DOI] 10.1021/acsptsci.0c00075. [PMID] 33344889.
2020
Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence.
Drug and alcohol dependence. 216 [DOI] 10.1016/j.drugalcdep.2020.108310. [PMID] 33017752.
2020
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
Journal of medicinal chemistry. 63(1):433-439 [DOI] 10.1021/acs.jmedchem.9b01465. [PMID] 31834797.
2020
Exploring 1-adamantanamine as an alternative amine moiety for metabolically labile azepane ring in newly synthesized benzo[d]thiazol-2(3H)one σ receptor ligands
Medicinal Chemistry Research. 29(9):1697-1706 [DOI] 10.1007/s00044-020-02597-2.
2020
Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids.
Toxicology letters. 319:148-154 [DOI] 10.1016/j.toxlet.2019.11.005. [PMID] 31707106.
2020
Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
Journal of ethnopharmacology. 249 [DOI] 10.1016/j.jep.2019.112462. [PMID] 31816368.
2020
Effects of Nutrient Fertility on Growth and Alkaloidal Content in Mitragyna speciosa (Kratom).
Frontiers in plant science. 11 [DOI] 10.3389/fpls.2020.597696. [PMID] 33408731.
2020
Evaluation of the rewarding effects of mitragynine and 7-hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats.
Drug and alcohol dependence. 215 [DOI] 10.1016/j.drugalcdep.2020.108235. [PMID] 32889450.
2020
Assessing the therapeutic potential and toxicity of Mitragyna speciosa in opioid use disorder.
Expert opinion on drug metabolism & toxicology. 1-3 [DOI] 10.1080/17425255.2021.1853706. [PMID] 33213215.
2020
Bioanalytical method development and pharmacokinetics of MCI-92, a sigma-1 receptor ligand.
Journal of pharmaceutical and biomedical analysis. 191 [DOI] 10.1016/j.jpba.2020.113610. [PMID] 32971495.
2020
Adolescent nicotine and tobacco smoke exposure enhances nicotine self-administration in female rats.
Neuropharmacology. 176 [DOI] 10.1016/j.neuropharm.2020.108243. [PMID] 32702403.
2020
Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies.
Journal of pharmaceutical and biomedical analysis. 180 [DOI] 10.1016/j.jpba.2019.113019. [PMID] 31838282.
2020
Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo.
The AAPS journal. 22(5) [DOI] 10.1208/s12248-020-00472-x. [PMID] 32691179.
2019
A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers.
Oncogene. 38(22):4264-4282 [DOI] 10.1038/s41388-019-0717-6. [PMID] 30718919.
2019
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.
Nature medicine. 25(12):1938-1947 [DOI] 10.1038/s41591-019-0668-z. [PMID] 31792461.
2019
Comparative Pharmacokinetics of Mitragynine after Oral Administration of Mitragyna speciosa (Kratom) Leaf Extracts in Rats.
Planta medica. 85(4):340-346 [DOI] 10.1055/a-0770-3683. [PMID] 30452072.
2019
Improved chemotherapy against breast cancer through immunotherapeutic activity of fucoidan decorated electrostatically assembled nanoparticles bearing doxorubicin
International Journal of Biological Macromolecules. 122:1100-1114 [DOI] 10.1016/j.ijbiomac.2018.09.059.
2019
Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom).
Xenobiotica; the fate of foreign compounds in biological systems. 49(11):1279-1288 [DOI] 10.1080/00498254.2018.1552819. [PMID] 30547698.
2019
Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry.
Drug testing and analysis. 11(8):1162-1171 [DOI] 10.1002/dta.2604. [PMID] 30997725.
2019
Bioanalytical method development and validation of MES207, a neuropeptide FF receptor antagonist, and its application in preclinical pharmacokinetics.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 1134-1135 [DOI] 10.1016/j.jchromb.2019.121875. [PMID] 31790916.
2018
A stable isotope dilution tandem mass spectrometry method of major kavalactones and its applications.
PloS one. 13(5) [DOI] 10.1371/journal.pone.0197940. [PMID] 29795658.
2017
A combination of complexation and self-nanoemulsifying drug delivery system for enhancing oral bioavailability and anticancer efficacy of curcumin.
Drug development and industrial pharmacy. 43(5):847-861 [DOI] 10.1080/03639045.2016.1239732. [PMID] 27648633.
2017
A pharmacokinetic comparison of homodimer ARB-92 and heterodimer ARB-89: novel, potent antimalarial candidates derived from 7β-hydroxyartemisinin
Journal of Pharmaceutical Investigation. 48(5):585-593 [DOI] 10.1007/s40005-017-0352-6.
2017
Doxorubicin Hydrochloride Loaded Zymosan-Polyethylenimine Biopolymeric Nanoparticles for Dual ‘Chemoimmunotherapeutic’ Intervention in Breast Cancer
Pharmaceutical Research. 34(9):1857-1871 [DOI] 10.1007/s11095-017-2195-2.
2017
Model based population PK-PD analysis of furosemide for BP lowering effect: A comparative study in primary and secondary hypertension
European Journal of Pharmaceutical Sciences. 109:253-261 [DOI] 10.1016/j.ejps.2017.08.009.
2017
Preclinical pharmacokinetics and ADME characterization of a novel anticancer chalcone, cardamonin.
Drug testing and analysis. 9(8):1124-1136 [DOI] 10.1002/dta.2128. [PMID] 27794181.
2017
Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study.
Drug testing and analysis. 9(8):1236-1242 [DOI] 10.1002/dta.2156. [PMID] 28039926.
2017
Simultaneous LC-MS-MS Determination of Lopinavir and Rifabutin in Human Plasma.
Journal of chromatographic science. 55(6):617-624 [DOI] 10.1093/chromsci/bmx016. [PMID] 28334925.
2017
Effect of arteether and pyrimethamine coadministration on the pharmacokinetic and pharmacodynamic profile of ormeloxifene.
Naunyn-Schmiedeberg's archives of pharmacology. 390(9):971-976 [DOI] 10.1007/s00210-017-1401-4. [PMID] 28689253.
2016
Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine.
Journal of medical toxicology : official journal of the American College of Medical Toxicology. 12(4):341-349 [PMID] 27752985.
View on: PubMed
2016
PK–PD interaction study of angiotensin II antagonist, losartan, with selective estrogen receptor modulator, centchroman
International Journal of Pharmacokinetics. 1(1):17-23 [DOI] 10.4155/ipk-2015-0001.
2016
LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma.
Bioanalysis. 8(6):533-45 [DOI] 10.4155/bio.16.7. [PMID] 26915470.
2016
Insights into the pharmacokinetic properties of antitubercular drugs.
Expert opinion on drug metabolism & toxicology. 12(7):765-78 [DOI] 10.1080/17425255.2016.1183643. [PMID] 27120703.
2016
Role of enterohepatic recirculation in drug disposition: cooperation and complications
Drug Metabolism Reviews. 48(2):281-327 [DOI] 10.3109/03602532.2016.1157600.
2016
Identification of gallic acid based glycoconjugates as a novel tubulin polymerization inhibitors.
Organic & biomolecular chemistry. 14(4):1338-58 [DOI] 10.1039/c5ob02113h. [PMID] 26659548.
2016
Identification of a diverse indole-2-carboxamides as a potent antileishmanial chemotypes
European Journal of Medicinal Chemistry. 110:237-245 [DOI] 10.1016/j.ejmech.2016.01.028.
2016
Ameliorative potential of ferulic acid in vincristine-induced painful neuropathy in rats: An evidence of behavioral and biochemical examination
Nutritional Neuroscience. 20(1):60-70 [DOI] 10.1179/1476830514y.0000000165.
2016
A mechanistic investigation of the bioavailability enhancing potential of lysergol, a novel bioenhancer, using curcumin
RSC Advances. 6(64):58933-58942 [DOI] 10.1039/c6ra09307h.
2016
Identification of β-Amino alcohol grafted 1,4,5 trisubstituted 1,2,3-triazoles as potent antimalarial agents.
European journal of medicinal chemistry. 109:187-98 [DOI] 10.1016/j.ejmech.2015.12.038. [PMID] 26774925.
2015
Coadministration of HMG-CoA reductase inhibitors, atorvastatin and rosuvastatin, does not affect contraceptive efficacy of centchroman.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. 20(3):231-5 [DOI] 10.3109/13625187.2015.1017756. [PMID] 25798535.
2015
Gender-related pharmacokinetics and bioavailability of a novel anticancer chalcone, cardamonin, in rats determined by liquid chromatography tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 986-987:23-30 [DOI] 10.1016/j.jchromb.2015.01.041. [PMID] 25703949.
2015
HPLC-MS-MS Method Development and Validation of Antileishmanial Agent, S010-0269, in Hamster Serum.
Journal of chromatographic science. 53(9):1542-8 [DOI] 10.1093/chromsci/bmv050. [PMID] 25935158.
2015
Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis
Bioorganic & Medicinal Chemistry. 23(4):742-752 [DOI] 10.1016/j.bmc.2014.12.060.
2015
Preclinical Evaluation of DMA, a Bisbenzimidazole, as Radioprotector: Toxicity, Pharmacokinetics, and Biodistribution Studies in Balb/c Mice.
Molecular pharmacology. 88(4):768-78 [DOI] 10.1124/mol.115.098376. [PMID] 26240287.
2015
Rapid quantitative analysis of ormeloxifene and its active metabolite, 7-desmethyl ormeloxifene, in rat plasma using liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 997:7-15 [DOI] 10.1016/j.jchromb.2015.05.034. [PMID] 26079264.
2014
Dried blood spots: concepts, present status, and future perspectives in bioanalysis.
Drug testing and analysis. 6(5):399-414 [DOI] 10.1002/dta.1646. [PMID] 24692095.
2014
Identification of Novel Phenyl Butenonyl C-Glycosides with Ureidyl and Sulfonamidyl Moieties as Antimalarial Agents
ACS Medicinal Chemistry Letters. 5(8):878-883 [DOI] 10.1021/ml500211c.
2014
Novel pre-clinical methodologies for pharmacokinetic drug–drug interaction studies: spotlight on “humanized” animal models
Drug Metabolism Reviews. 46(4):475-493 [DOI] 10.3109/03602532.2014.967866.
2013
Discovery of a new class of natural product-inspired quinazolinone hybrid as potent antileishmanial agents.
Journal of medicinal chemistry. 56(11):4374-92 [DOI] 10.1021/jm400053v. [PMID] 23611626.
2013
Synthesis and bioevaluation of novel 4-aminoquinoline-tetrazole derivatives as potent antimalarial agents
European Journal of Medicinal Chemistry. 66:69-81 [DOI] 10.1016/j.ejmech.2013.05.023.

Grants

Jan 2021 ACTIVE
Developing a Novel PROTAC-Based NR4A1 Degrader for Breast Cancer Therapy
Role: Other
Funding: US ARMY MED RES ACQUISITION
Dec 2020 ACTIVE
Opioid use disorders: UF Pharmacy medications discovery and development
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDA
Sep 2020 ACTIVE
Opioid and cannabinoid interactions in pain and reward
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDA
Sep 2019 ACTIVE
A phased clinical trial of a dietary supplement kava: biomarker changes and anxiolytic effects
Role: Faculty
Funding: NATL CTR FOR COMPLEM AND INTEGRATIVE HLT
Apr 2019 ACTIVE
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDA

Education

Ph.D.
2015 · CSIR-Central Drug Research Institute
M.Pharm.
2008 · U. P. Technical University
B.Pharm.
2006 · Mohan Lal Sukhadia University

Teaching Profile

Courses Taught
2020-2021
GMS6009 Principles of Drug Action and Therapeutics

Contact Details

Phones:
Business:
(352) 273-7851
Emails: